The “business of diabetes” did not spontaneously emerge mid-century. Corporate stakeholders found underhanded ways to profit from diabetic lives before most affected individuals had even obtained their first injection. And now that Congress is investigating insulin manufacturers, it is important to acknowledge the full scope of their involvement. Read more
I’m thrilled to see the recent buzz in the media concerning the high insulin costs many diabetics face daily in the USA. I’ve required insulin multiple times a day for 33+ years and I have a high deductible insurance policy which means medical costs, including prescriptions, aren't covered until the deductible is met. I paid $1,003.91 for insulin this month. That cost is what I paid with insurance and a $150 discount card. I pay high amounts during the first few months of every year until I meet my deductible. Read more
Patient-led activism is working. Today Eli Lilly announced that in response to criticism of high prices, the company will sell a version of Humalog insulin for half price. We are pleased to see this result after continual and dedicated efforts by non-pharma funded patient advocates to ensure list price of insulin goes down. While half-price is an improvement, it's still an unaffordable price for so many, considering most people need at least 2 vials each month.
The #insulin4all USA Chapters are building a coordinated movement to ensure insulin is affordable and accessible to all people with type 1 diabetes. Their efforts are leading to real change at both the State and Federal level. Read more
Micah rationed his Novalog not only because it made him sick, but because he had difficulty affording both it and the Humalog. As a result of his rationing, Micah ended up in a diabetic coma from which he could not be revived, despite hours of efforts by many medical staff. He died that night at the age of 26. Read more
The perfect storm does not warn you that it will be different than any other you have weathered. On top of her other worries, the company that produced the insulin pump Meaghan was using had recently gone out of business. Without a job or insurance, it was impossible to purchase supplies, much less a different pump. At the time, Meaghan had two short term jobs but had not had them long enough to get insurance. She had another job lined up to start the week after Christmas and she would have been okay. She wasn't.
Last month, Hoosiers living with type 1 diabetes delivered to the Indiana General Assembly a petition signed by over 500 people demanding that the House Public Health Committee hear a bill to establish a study committee on rising prescription drug prices. Their efforts have paid off. Committee Chair Rep. Cindy Kirchhofer has set the legislation, House Bill 1029, for hearing on Wednesday, February 6th at 3:30 PM in the House chamber. Read more
T1International is excited to announce the expansion of our USA work to address the insulin price crisis in America. Thanks to a grant from the Laura and John Arnold Foundation (LJAF), we have brought on board a US Program Manager consultant to help us build our grassroots State Chapters and give people with type 1 diabetes a stronger presence in policy-making. Read more
Why does insulin cost so much to patients in the USA and around the world? Why is insulin, a widely sold drug of which most forms are now off-patent, so incredibly expensive? These are simple questions, but ones with a number of complicated answers. This post will break some of those answers down and point you in the direction further reading if you want to dive deeper. Read more
Sanofi and Novo Nordisk are celebrating the New Year with fresh price hikes on their decades-old insulin products. “Sanofi increased the price of its three main insulin brands by between 4.4 %- 5.2 % last week, while Novo Nordisk increased the price of its insulin products by just under 5% on Tuesday,” the Financial Times article said. Once again, shareholder profits will be increased on the backs of people with diabetes. Read more